Zenas BioPharma (ZBIO) Cash from Operations (2023 - 2026)

Zenas BioPharma's Cash from Operations history runs 4 years deep, the most recent figure standing at 75196000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 102.95% year-over-year to 75196000.0 in Q1 2026; TTM through Mar 2026 was 210478000.0, a 52.94% decrease from a year earlier, with the FY2025 full-year figure at 172333000.0, down 44.0% from the prior year.
• Cash from Operations fell to 75196000.0 in Q1 2026 per ZBIO's latest filing, from 52414000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 15400000.0 in Q4 2023 and bottomed at 75196000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 37802500.0 (2024), against an average of 38260300.0.
• Across the five-year window, Cash from Operations tumbled 150.35% in 2024 and slumped 32.41% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 15400000.0 in 2023, then plunged by 150.35% to 38554000.0 in 2024, then plunged by 35.95% to 52414000.0 in 2025, then plunged by 43.47% to 75196000.0 in 2026.
• Per Business Quant, the three latest ZBIO Cash from Operations figures stand at 75196000.0 (Q1 2026), 52414000.0 (Q4 2025), and 41125000.0 (Q3 2025).